Futura Medical has filed a new formulation patent for its topical gel for the treatment of erectile dysfunction, with the UK Intellectual Property Office in connection with MED2002.
According to Futura, this patent application has the potential to extend MED2002’s patent life worldwide through to 2038, thereby significantly increasing the opportunity for licensing partners to generate higher revenues and profits from the commercialisation of MED2002.
The new patent includes intellectual property confirmed by the Futura Medical’s pivotal efficacy study of MED2002, the results of which were announced in September 2016.
MED2002’s current patent protection runs until August 2028 in the USA and August 2025 in Europe.
James Barder, Futura’s Chief Executive, said: “This latest patent filing has the potential to extend MED2002’s patent protection worldwide through to 2038, significantly extending the product’s commercial window and increasing its attractiveness to licensing partners.”